Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome

Lupus

Volumn 12, Issue 8, 2003, Pages 633-635

  Alba, P ^a   Karim, M Y ^a   Hunt, Beverly J ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Autoimmune haemolytic anaemia; Lupus; Mycophenolate mofetil

Indexed keywords

FERROUS SULFATE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRON DEFICIENCY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADULT; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIPHOSPHOLIPID SYNDROME; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 0042466330     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu419cr     Document Type: Article

References (12)

1. Keeling DM, Isenberg DA. Haematological manifestations of systemic lupus erythematosus. Blood Rev 1993; 7: 199-207.
2. Drenkard C, Villa AR, Alarcon Segovia D et al. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol 1994; 21: 1067-1072.
3. Roldan R, Roman J, Lopez D et al. Treatment of hemolytic anemia and severe thrombocytopenia with high dose methylprednisolone and intravenous immunoglobulins in SLE. Scand J Rheumatol 1994; 23: 218-219.
4. Halloran P, Mathew T, Tomlanovich S et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomised double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 39-47.
5. Smak Gregoor PJH, van Gelder T, Weimar W. Mycophenolate mofetil, Cellcept, a new immunosuppressive drug with great potential in internal medicine. Netherlands J Med 2000; 57: 233-246.
6. Karim MY, Alba P, Cuadrado MJ et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002; 41: 876-882.
7. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil. Transplant 1996; 10: 77-84.
8. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephrifis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 34: 1156-1162.
9. Zimmer-Molsberger B, Knauf W, Thiel E. Mycophenolate mofetil for severe autoimmune haemolytic anaemia. Lancet 1997; 350: 1003-1004.
10. Howard J, Hoffbran AV, Prentice HG et al. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and autoimmune thrombocytopenia purpura. Br J Haematol 2002; 117: 712-715.
11. Arbeiter K, Greenbaum L, Balzar E et al. Reproducible erythroid aplasia caused by mycophenolate mofetil. Pediatr Nephrol 2000; 14: 195-197.
12. Kokori SIG, Ioannidis JPA, Voulgarelis M et al. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. Am J Med 2000; 108: 198-203.